B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

EIF2AK4

MOLECULAR TARGET

eukaryotic translation initiation factor 2 alpha kinase 4

UniProt: Q9P2K8NCBI Gene: 44027522 compounds

EIF2AK4 (eukaryotic translation initiation factor 2 alpha kinase 4) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting EIF2AK4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1erlotinib5.55256
2tozasertib4.3375
3bosutinib4.0858
4midostaurin3.8546
5neratinib3.6638
6nintedanib3.6136
7pelitinib3.5032
8tae 6843.4330
9fedratinib3.4029
10dovitinib3.0921
11jnj 77066213.0921
12lestaurtinib3.0420
13r 4062.8316
14pha 6657522.7114
15plx 47202.7114
16kw 24492.6413
17raf 2652.4811
18motesanib2.4811
19gsk 4613642.4010
20su 0148132.208
21ly 30091202.087
22Dasatinib0.691

About EIF2AK4 as a Drug Target

EIF2AK4 (eukaryotic translation initiation factor 2 alpha kinase 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented EIF2AK4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

EIF2AK4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.